Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Donohue

Emergency Medicine Savannah, GA Medical Doctor

NPI 1427099522 CMS profile 246558

5356 Reynolds St, 201, Savannah, GA 31405

Open in the dashboard

General payments

$6,449

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Donohue of Savannah, GA is reported in the CMS Open Payments database as having received $6,449 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,917 36
2024 General $903 17
2023 General $817 22
2022 General $666 15
2021 General $575 21
2020 General $859 24
2019 General $711 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Donohue
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Thomas Donohue were reported at $1,917. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Thomas Donohue Emergency Medicine median Middle half National median
2019 $711 $51 $18–$128 $163
2020 $859 $29 $16–$99 $114
2021 $575 $40 $18–$124 $132
2022 $666 $49 $20–$134 $149
2023 $817 $51 $22–$142 $160
2024 $903 $52 $22–$150 $164
2025 $1,917 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,607 63 payments
  2. Organogenesis Inc. $1,585 23 payments
  3. LifeNet Health $837 7 payments
  4. Integra LifeSciences Corporation $471 14 payments
  5. RedDress USA, Inc. $363 4 payments
  6. Kerecis Limited $309 4 payments
  7. Next Science LLC $219 5 payments
  8. Vertex Pharmaceuticals Incorporated $184 2 payments
  9. MIMEDX Group, Inc. $179 2 payments
  10. Misonix Inc $145 8 payments
  11. Other $550 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,736 150 payments
  2. Travel and Lodging $603 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $110 1 payment
Products named General payments · program years 2019–2025
  1. TheraGenesis Wound Matrix $837 7 payments
  2. Puraply $654 9 payments
  3. PICO $463 13 payments
  4. GRAFIX PL $414 9 payments
  5. COLLAGENASE SANTYL $410 23 payments
  6. TCC-EZ $353 12 payments
  7. PRIMATRIX $353 12 payments
  8. AMNIOEXCEL $353 12 payments
  9. MEDIHONEY $353 12 payments
  10. OMNIGRAFT $353 12 payments
  11. Other $6,554 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

114

Median for Emergency Medicine: 88

Drug cost

$17,824

Median for Emergency Medicine: $590

Branded share of claims

23.7%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 12 $16,775
Doxycycline Monohydrate Generic 37 $355
Cefdinir Generic 13 $349
Ciprofloxacin Hcl Generic 24 $183
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 15 $87
Metronidazole Generic 13 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$83,457

Medicare's payments for the services billed

Medicare patients

146

Average age 76

Services billed

1,650

75 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 53%
Chronic kidney disease 47%
Atrial fibrillation 32%
Depression 32%
Heart failure 30%
Ischemic heart disease 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record